Últimas noticias sobre Hoth Therapeutics (NASDAQ:HOTH) Bolsa

HOTH THERAPEUTICS INC

Hoth Therapeutics

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Markets

Trading Ideas

APLD

EAST

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SGLY

SIFY

Mercados mixtos en EE.UU. el jueves, con el Nasdaq subiendo un 0,2% y Dow Jones ganando un 0,06%. Sectores de consumo lideran alzas.

Mercados mixtos mientras los subsidios por desempleo de EEUU caen

Hoth Therapeutics Inc

Bank of America Securities (BofA) analyst Brad Sills <a target="_blank" href="https://www.benzinga.com/quote/HUBS/analyst-ratings" rel="noreferrer noopener">maintained a Buy</a> rating on HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a price forecast of $740 on Monday.
Sills took a deep dive into the key components of HubSpot&#8217;s emerging Breeze AI platform.
The analyst doesn&#8217;t expect material revenue from Breeze until fiscal 2027, but he notes it&#8217;s a useful exercise to take a bottoms-up approach to model incremental revenue from Breeze.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45755544/rising-ai-analytics-budgets-could-lift-microsoft-snowflake-datadog" rel="noreferrer noopener">Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog</a>
Sills asserted that the point of the modeling exercise is not to predict the timing of revenue but to illustrate Breeze AI can move the needle on growth without heroic assumptions, given the value of the offerings and scale of HubSpot&#8217;s installed base.
Like Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), the analyst noted that the use case for AI is most compelling in HubSpot&#8217;s sales and marketing categories, given the promise of sales productivity and potential revenue uplift.
However, he noted that in HubSpot&#8217;s small to medium-sized business (SMB) end market, third-party agentic tools like ChatGPT could substitute for agents.
Channel feedback suggested HubSpot customers do not have the same restriction on third-party tools that enterprises do and are running these tools for basic generative use cases such as marketing content, Sills noted.
Sills added that this means Breeze agents need to solve more sophisticated workflows to drive adoption.
He said HubSpot has&nbsp;a robust set of agents, including customer agents, content agents, social media agents, prospecting agents, and knowledge base agents.
Sills noted that these agents can drive meaningful workflow automation over time because they run on a proprietary and robust data set.
HubSpot manages over 200 million company and buyer profiles, the analyst noted. Also, with the acquisition of Frame AI, he said Breeze can ingest vast amounts of unstructured data.
On May 8, the company expanded the use of HubSpot credits to Customer Agent across Marketing, Sales, Service, and all other core hubs, Sills noted.
Pro and Enterprise customers will have a baseline credit package per month and can purchase more credits at $10/1000 credits, the analyst said.
In a Customer Agent base case, assuming 2.5% and 3% agent penetration and 10% and 13% resolution rate, Sills arrived at $30 million and $ 84 million of revenue contribution in fiscal 2026 and 2027, representing 1% and 2% points of growth, respectively.
Sills projected fiscal 2025 sales of $3.04 billion and EPS of $9.33.
Price Action: HUBS stock is up 1.08% at $540.26 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672420/pros-global-e-sps-commerce-stand-out-as-tariffs-reshape-software-spending-priorities-analyst" target="_blank" rel="noreferrer noopener">PROS, Global-E, SPS Commerce Stand Out As Tariffs Reshape Software Spending Priorities: Analyst</a></li>
</ul>
Image via Shutterstock

Price Target

Reiteration

Analyst Ratings

HUBS

HubSpot's Breeze AI Platform Could Add Millions In Revenue By 2027: Analyst

CRWD

FTNT

LDOS

CNBC Halftime Report Final Trades: Global X Cybersecurity ETF, CrowdStrike, Leidos Holdings, Fortinet

<a href="https://x.com/AndrewDudum/status/1937188022027768304" title="https://x.com/AndrewDudum/status/1937188022027768304">https://x.com/AndrewDudum/status/1937188022027768304</a>

Asset Sales

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health CEO Andrew Dudum Posts To X "Co Will Continue To Offer Access To A Range Of Treatments, Including Wegovy, "Disappointed To See Novo Nordisk Management Misleading The Public", "Novo's Commercial Team "Increasingly Pressured" Co In Recent Weeks To Control Clinical Standards, Steer Patients To Wegovy",  "Co Will Not Compromise The Integrity Of Its Platform"

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) is on the verge of a golden moment — literally. The stock is just about to make <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a>, a classic technical indicator where the 50-day moving average crosses above the 200-day, signaling a potential bullish turn.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623"><img loading="lazy" decoding="async" width="627" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23113840/Screenshot-2025-06-23-at-5.44.54-PM.png" alt="" class="wp-image-958351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23113840/Screenshot-2025-06-23-at-5.44.54-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23113840/Screenshot-2025-06-23-at-5.44.54-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0623" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Honeywell stock, at $221.80, is poised to flip its trend from cautious to confident, with technicals hinting at a subtle shift in investor sentiment despite a moderately bearish backdrop.
Read Also: <a href="https://www.benzinga.com/insights/news/25/06/46040482/1000-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today">$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today</a>
<h1 class="wp-block-heading">On The Cusp Of A Golden Cross</h1>
Honeywell's 50-day simple moving average (SMA) sits at $215.17, edging close to crossing above the 200-day average at $215.40. Although short-term signals like the eight-day SMA ($224.00) and 20-day SMA ($225.14) suggest some near-term selling pressure, longer-term indicators are more optimistic.
The MACD (moving average convergence/divergence) indicator at 1.54 and an RSI (relative strength index) hovering near neutral at 48.85 point to growing buying interest, setting the stage for a potential technical breakout.
<h1 class="wp-block-heading">Strategic Shakeup Powers Investor Interest</h1>
This technical setup aligns neatly with Honeywell's ongoing transformation. The company is deep into a major portfolio restructuring, carving itself into three independent, publicly traded firms by mid-2026. Following the <a href="https://www.honeywell.com/us/en/press/2025/03/honeywell-announces-leadership-team-and-company-name-for-advanced-materials-spin-off">planned spin-off</a> of its Advanced Materials division, Honeywell aims to sharpen focus on its core strengths: Automation, Aerospace Technologies, and Energy Transition.
The recent <a href="http://www.msn.com/en-us/money/topstocks/honeywell-finalizes-sundyne-acquisition-to-boost-its-process-industry-strength/ar-AA1Gx6uW?apiversion=v2&amp;noservercache=1&amp;domshim=1&amp;renderwebcomponents=1&amp;wcseo=1&amp;batchservertelemetry=1&amp;noservertelemetry=1">acquisitions</a> and <a href="https://www.prnewswire.com/news-releases/honeywell-completes-sale-of-personal-protective-equipment-business-to-protective-industrial-products-302463656.html">sale</a> of its Personal Protective Equipment business for over $1.3 billion underscore Honeywell's commitment to streamline operations and boost shareholder value.
<h1 class="wp-block-heading">Flying High With Aerospace Innovation</h1>
Honeywell is also revving up in aerospace, expanding its <a href="https://www.honeywell.com/us/en/press/2025/01/honeywell-and-nxp-expand-partnership-to-accelerate-next-generation-aviation-technology">partnership</a> with NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) to accelerate autonomous flight tech.
The showcase of its Anthem avionics system at CES 2025 and the new U.S. government contract for speech anonymization tech highlight Honeywell's drive to stay at the cutting edge of aviation safety and privacy.
<h1 class="wp-block-heading">Why It Matters For Investors</h1>
The Golden Cross isn't just a technical blip — it could be a subtle signal that Honeywell's evolving business strategy is starting to resonate with the market. If the cross completes and the stock sustains above key moving averages, investors might see this as a cue that Honeywell is ready to take off after a period of sideways action.
With its diversified portfolio focused on high-growth megatrends and a clearer business structure on the horizon, Honeywell's golden cross could mark the beginning of a new chapter in shareholder returns.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46035394/honeywell-itt-eaton-see-bright-outlook-as-bofa-securities-cites-military-spending-aftermarket-growth">Honeywell, ITT, Eaton See Bright Outlook As BofA Securities Cites Military Spending, Aftermarket Growth</a></li>
</ul>
Photo: Piotr Swat via Shutterstock

Technicals

Signals

NXPI

Golden Cross Alert: Honeywell Nears A Bullish Breakout As Strategic Shakeup Gains Traction

In the current market session, Catalyst Bancorp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLST#NASDAQ">CLST</a>) stock price is at $12.00, after a 1.88% decrease. However, over the past month, the company's stock went up by 6.79%, and in the past year, by 8.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750698033_0.png" alt="Past Year Chart" />

<h3>Evaluating Catalyst Bancorp P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 86.94 in the Banks industry, Catalyst Bancorp Inc. has a lower P/E ratio of 23.08. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750698034_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

CLST

Price Over Earnings Overview: Catalyst Bancorp

M&amp;T Bank's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) short percent of float has risen 13.62% since its last report. The company recently reported that it has 4.10 million shares sold short, which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>M&amp;T Bank Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698031_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for M&amp;T Bank has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing M&amp;T Bank's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, M&amp;T Bank's peer group average for short interest as a percentage of float is 4.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is M&T Bank Gaining or Losing Market Support?

Airbnb's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NYSE">ABNB</a>) short percent of float has risen 3.01% since its last report. The company recently reported that it has 16.09 million shares sold short, which is 3.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Airbnb Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698026_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Airbnb has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Airbnb's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Airbnb's peer group average for short interest as a percentage of float is 7.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ABNB

Peering Into Airbnb's Recent Short Interest

Enbridge's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) short percent of float has fallen 58.38% since its last report. The company recently reported that it has 31.27 million shares sold short, which is 1.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Enbridge Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750698021_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Enbridge has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Enbridge's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Enbridge's peer group average for short interest as a percentage of float is 3.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Enbridge Gaining or Losing Market Support?

<a href="https://www.bloomberg.com/news/live-blog/2025-06-23/middle-east-latest">https://www.bloomberg.com/news/live-blog/2025-06-23/middle-east-latest</a>

Macro Economic Events

Politics

Economics

General

iShares MSCI Israel Capped Investable Market Index Fund

'Iran Launches Missiles Toward US Base in Qatar'- Bloomberg

WIIM

OCGN

Ocugen shares are trading lower after after the company's subsidiary, Ocugen, and Carisma Therapeutics entered into a  definitive merger agreement to combine the companies in an all-stock transaction

Reuters Cites Military Sources Saying Air Defense System Activated In US Ain Al-Asad Airbase In Iraq For Fear Of A Potential Attack; Maximum Alert Status Declared, Orders Issued To Take Shelter In Bunkers At Ain Al-Asad Airbase In Iraq

SCHL

Scholastic shares are trading higher after the company issued FY25 adjusted EBITDA results.

RNEW

Trading Halt: Halted at 12:49:24 p.m. ET - Trading Halt: Halt News Pending

CAPR

Capricor Therapeutics shares are trading lower after Oppenheimer maintained an Outperform rating on the stock and lowered its price target from $43 to $22.

CLBR

Colombier Acquisition Corp. II shares are trading higher after the SEC declared the registration statement on Form S-4 in connection with its proposed business combination with GrabAGun effective.

Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">data from Benzinga Pro</a>.
According to a Friday media report, Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), canceled the advisory committee meeting for the company's cell therapy for Duchenne muscular dystrophy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46036263/capricor-reports-4-year-data-for-deramiocel-shows-sustained-benefit-in-duchenne-patients" rel="noreferrer noopener">Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients</a>
Earlier in June, the FDA&#8217;s Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the company&#8217;s lead cell therapy candidate with a Biologics License Application (BLA) under FDA review for potential approval in the treatment of <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, 2025, although that date is pending confirmation by the FDA. At the time of the mid-cycle review, no significant issues or major <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45882991/capricor-therapeutics-announces-key-regulatory-updates-for-its-duchenne-muscular-dystrophy-program" rel="noreferrer noopener">deficiencies were noted</a>.
The BLA for Deramiocel remains under priority review with a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025.
STAT News <a href="https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/">reported </a>that the FDA removed its top official overseeing cell and gene therapies shortly after a dispute with her superior over a treatment for Duchenne muscular dystrophy.
The official, Nicole Verdun, had planned to convene an advisory committee meeting to evaluate a therapy developed by Capricor Therapeutics. However, to STAT, Prasad — her superior — doubted the treatment's effectiveness and canceled the meeting, citing sources familiar with the matter.
The report also noted that some sources described ongoing tensions surrounding Verdun's management style, adding uncertainty about the reasons she was placed on leave.
Since the report on Friday, Capricor stock has plunged almost 30%.
Alliance for Regenerative Medicine (ARM), an advocacy organization, <a target="_blank" href="https://alliancerm.org/press-release/statement-on-the-departure-of-otp-director/" rel="noreferrer noopener">said</a> with five regulatory decisions pending on cell and gene therapy (CGT) products in 2025 and a burgeoning pipeline of nearly 2,000 CGT clinical trials ongoing globally, CBER and OTP must operate at the highest level of productivity, efficiency, and scientific rigor.
Price Action: CAPR stock is down 11.6% at $7.30 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

Movers

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

DJT stock has given up its prior gain. Trump Media shares were trading higher after the company announced a $400 million share repurchase authorization.

ZYBT

Zhengye Biotechnology Holding shares are trading lower after the company announced it received a Nasdaq noncompliance notice.

Rumors

Reuters Citing A Witness Says Explosions Heard Over Qatar Capital Doha

JP Morgan analyst Jeremy Tonet maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $311 to $380.

JP Morgan Maintains Overweight on Constellation Energy, Raises Price Target to $380

Press Releases

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

/C O R R E C T I O N -- Hoth Therapeutics, Inc./

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Comments

Hoth Therapeutics

Noticias

Últimas noticias sobre Hoth Therapeutics (NASDAQ:HOTH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL